CMBA
OSIR

C.M. Bidwell & Associates’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History

C.M. Bidwell & Associates’s Portfolio OSIR Stock Details OSIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-10,275
Closed -$160K – 331
2014
Q2 		$160K Hold
10,275
– – 0.04% 178
2014
Q1 		$135K Hold
10,275
– – 0.03% 179
2013
Q4 		$165K Buy
+10,275
New +$164K 0.04% 183

Other funds holding OSIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

C.M. Bidwell & Associates's OSIR Position: Q3 2014 in Review

C.M. Bidwell & Associates sold out of Osiris Therapeutics, Inc. Common Stock (OSIR) in Q3 2014, closing a stake of 10,275 shares — an estimated $160K sold.

C.M. Bidwell & Associates first reported a position in OSIR in Q4 2013 and held it in 3 quarters. The position peaked at $165K in Q4 2013. 67 funds tracked by Wall St. Rank hold OSIR as of Q3 2014.

  • C.M. Bidwell & Associates reported no remaining Osiris Therapeutics, Inc. Common Stock position as of Q3 2014 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 10,275 Osiris Therapeutics, Inc. Common Stock shares in Q3 2014, an estimated $160K.
  • C.M. Bidwell & Associates first reported a position in Osiris Therapeutics, Inc. Common Stock in Q4 2013 and held it in 3 quarters.
  • C.M. Bidwell & Associates's Osiris Therapeutics, Inc. Common Stock position peaked at $165K in Q4 2013.
  • 67 funds tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q3 2014.

Based on C.M. Bidwell & Associates's 13F filing for Q3 2014, filed 14 Nov 2014.